ReviewDiscovery medicine2012
Advances in management of acute hypertension: a concise review.
Review in Discovery medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pooled it
- Neurovascular Complications of Acute Aortic Syndrome.Journal of stroke · 2025Review
- Nose-to-Heart Approach: Unveiling an Alternative Route of Acute Treatment.Biomedicines · 2024Review
- In-hospital outcomes of patients with a hypertensive emergency at a medical center, Ethiopia: A prospective observational study.Health science reports · 2022Article
- Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy.Journal of veterinary internal medicine · 2022Article
- Posterior reversible encephalopathy syndrome presenting with thrombotic microangiopathy triggered by malignant hypertension: a case report and literature review.BMJ neurology open · 2022Article
- Hypertensive crisis: clinical characteristics of patients with hypertensive urgency, emergency and pseudocrisis at a public emergency department.Einstein (Sao Paulo, Brazil) · 2019Article
- Scleroderma renal crisis: a review for emergency physicians.Internal and emergency medicine · 2019Review
- Targeting Pim Kinases and DAPK3 to Control Hypertension.Cell chemical biology · 2018Article
- Management of hypertensive crises in the elderly.Journal of geriatric cardiology : JGC · 2018Review
- Therapeutic Approach to Hypertension Urgencies and Emergencies in the Emergency Room.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2018Review
- Association between in-hospital acute hypertensive episodes and outcomes in older trauma patients.Internal and emergency medicine · 2014Article
- Current and newer agents for hypertensive emergencies.Current hypertension reports · 2014Review
- Perioperative acute hypertension-role of Clevidipine butyrate.Frontiers in pharmacology · 2014Article
- Mechanisms of load dependency of myocardial ischemia reperfusion injury.American journal of cardiovascular disease · 2013Review
- Control of bleeding in endoscopic skull base surgery: current concepts to improve hemostasis.ISRN surgery · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Chronic hypertension affects >1 billion people worldwide and >70 million people in the United States. Acute hypertensive episodes (AHE) are defined as severe spikes in blood pressure that may result in end-organ damage. Although AHE may arise independently as de novo events, they are more likely to occur in patients with pre-existing hypertension. One of the controversies regarding the clinical approach to AHE is the selection of anti-hypertensive medication. Depending on the clinical presentation of the patient and the threat of end-organ damage resulting from blood pressure elevation, appropriate and prompt treatment is warranted. There are multiple agents available for the management of hypertension. However, the greatest challenge lies in the acute care setting where the need exists for better initial and sustained control of blood pressure spikes. Many anti-hypertensive agents effectively lower blood pressure, yet only few have the capacity to achieve strict control of hypertension in the acute setting. Clevidipine butyrate is an ultra short-acting intravenous dihydropyridine calcium-channel blocker. Clevidipine has unique pharmacodynamic and pharmacokinetic properties that enable the fast, safe, and adequate reduction of blood pressure in hypertensive emergencies, with the ability to provide highly precise titration necessary to maintain a narrowly-defined target blood pressure range. Several recently published phase I, II, and III clinical studies have shown Clevidipine to be an effective blood pressure modulator in such capacity.
Indexed as
Identifiers
22642919PMC3727280W1560135745What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.